Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SLXN
SILEXION THERAPEUTICS LTD.
NASDAQ
$0.36
▲ UP 0.72% (0.00)

KEY STATISTICS

Market Cap$152.01 K
52w High$77.70
52w Low$0.35
Dividend Yield—
Frequency—
P/E-0.01
Volume72.77K
Shares Out.419.00K

COMPANY

LEADERSHIP

Ilan Hadar
CHIEF EXECUTIVE
Ilan Hadar

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 16, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
14

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2026-05-29Reverse1:10
2025-07-29Reverse1:15
2024-11-29Reverse1:9

PRICE

$0.36 ▲ UP 0.72% (+$0.00)
OVERLAYS
$0.36$0.36$0.36$0.379:36 AM10:38 AM11:41 AM12:43 PM1:45 PM2:48 PM3:50 PM0.36

About Silexion Therapeutics Ltd.

https://silexion.com ↗

Silexion Therapeutics LTD develops RNAi-based cancer therapies using its proprietary LODER delivery platform for solid tumors like pancreatic, prostate, and glioblastoma, with several products in pre-clinical and clinical stages.

INDUSTRY

Biotechnology

A PRODUCT SILEXION THERAPEUTICS LTD. IS KNOWN FOR

SIL204
SIL204

SIL204 is a clinical-stage RNAi therapy targeting mutated KRAS oncogenes in aggressive solid tumors, primarily for locally advanced pancreatic cancer, with Phase 2/3 trials planned for 2026.

COMPETITORS

COMPETITOR
ALNY COMPARE
ARWR COMPARE
RNA COMPARE

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHAIRMAN AND CEO
Hadar Ilan
Purchase · 10.0K shares
2026-06-04
★
OFFICER: CFO AND SECRETARY
Horenshtein Hadar Mirit
Purchase · 7.5K shares
2026-06-04
★
OFFICER: CSO AND CDO
Shirvan Mitchell
Purchase · 6.0K shares
2026-06-04
★
OFFICER: CSO AND CDO
Shirvan Mitchell
Sale · 22.8K shares
2026-03-26

SECTORS PEERS

PEERPRICE
INDP$1.14COMPARE
JSPR$0.70COMPARE
ONCO$0.61COMPARE
PTIX$0.98COMPARE
ENVB$1.37COMPARE
SPRC$6.58COMPARE
LIPO$0.00COMPARE
SCNI$2.51COMPARE